Trending NewsTrending NewsMost-Downgraded StocksMost-DowngradedNASDAQ:RARE Ultragenyx Pharmaceutical (RARE) Stock Price, News & Analysis $15.29 +0.40 (+2.69%) Closing price 04:00 PM EasternExtended Trading$15.25 -0.04 (-0.29%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Ultragenyx Pharmaceutical Stock (NASDAQ:RARE) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RARE alerts:Sign Up Key Stats Today's Range$14.43▼$15.5250-Day Range$12.88▼$26.9652-Week Range$12.73▼$39.89Volume5.40 million shsAverage Volume5.61 million shsMarket Capitalization$1.51 billionP/E RatioN/ADividend YieldN/APrice Target$34.58Consensus RatingHold Company Overview Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic diseases. The company targets conditions with limited or no treatment options, including metabolic disorders, skeletal diseases and other inherited conditions. Its work includes the development of medicines, biologic therapies and gene therapy candidates intended to address the underlying causes or significant symptoms of these disorders. Ultragenyx’s commercial portfolio includes Crysvita (burosumab), a treatment for X-linked hypophosphatemia and related disorders; Dojolvi (triheptanoin), a medical food used to manage long-chain fatty acid oxidation disorders; and Mepsevii (vestronidase alfa), an enzyme replacement therapy for mucopolysaccharidosis VII. The company also maintains a pipeline of investigational therapies, including gene therapy programs for rare diseases. Founded in 2010 by physician-scientist Emil Kakkis, Ultragenyx is headquartered in Novato, California. Kakkis serves as the company’s chief executive officer and has led its focus on rare-disease drug development. Ultragenyx serves patients and healthcare providers in the United States and international markets through its commercial operations, partnerships and regional distribution arrangements.AI Generated. May Contain Errors. Read More Ultragenyx Pharmaceutical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks70th Percentile Overall ScoreRARE MarketRank™: Ultragenyx Pharmaceutical scored higher than 70% of companies evaluated by MarketBeat, and ranked 201st out of 884 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingUltragenyx Pharmaceutical has received a consensus rating of Hold. The company's average rating score is 2.48, and is based on 1 strong buy rating, 9 buy ratings, 10 hold ratings, and 1 sell rating.Upside PotentialUltragenyx Pharmaceutical has a consensus price target of $34.58, representing about 126.2% upside from its current price of $15.29.Amount of Analyst CoverageUltragenyx Pharmaceutical has been the subject of 19 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Ultragenyx Pharmaceutical's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ultragenyx Pharmaceutical are expected to grow in the coming year, from ($3.96) to ($0.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ultragenyx Pharmaceutical is -2.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ultragenyx Pharmaceutical is -2.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Ultragenyx Pharmaceutical's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted17.73% of the float of Ultragenyx Pharmaceutical has been sold short.Short Interest Ratio / Days to CoverUltragenyx Pharmaceutical has a short interest ratio ("days to cover") of 2.22, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ultragenyx Pharmaceutical has recently decreased by 3.34%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldUltragenyx Pharmaceutical does not currently pay a dividend.Dividend GrowthUltragenyx Pharmaceutical does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.21 News SentimentUltragenyx Pharmaceutical has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.40 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Ultragenyx Pharmaceutical this week, compared to 10 articles on an average week.Search Interest33 people have searched for RARE on MarketBeat in the last 30 days. This is an increase of 22% compared to the previous 30 days.MarketBeat FollowsOnly 7 people have added Ultragenyx Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of -53% compared to the previous 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Ultragenyx Pharmaceutical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $19,663.00 in company stock.Percentage Held by Insiders5.20% of the stock of Ultragenyx Pharmaceutical is held by insiders.Percentage Held by Institutions97.67% of the stock of Ultragenyx Pharmaceutical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ultragenyx Pharmaceutical's insider trading history. Receive RARE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ultragenyx Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RARE Stock News HeadlinesIs Ultragenyx Pharmaceutical (RARE) Undervalued Following EMA Validation For Its Sanfilippo Gene Therapy?October 8 at 7:15 PM | finance.yahoo.comUltragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 MillionOctober 7 at 2:19 PM | marketscreener.comMChina ATTACK on American Dollar set for 11/12/2026A former Wall Street Journal personal finance expert warns China may be setting the stage for a major move against the US dollar, with a possible flashpoint on November 12, 2026. He lays out five steps he believes every American should consider taking before that date arrives.October 8 at 1:00 AM | International Living (Ad)Ultragenyx To Sell Rare Pediatric Disease Voucher For $210 MlnOctober 7 at 2:19 PM | rttnews.comUltragenyx lands $210M deal to sell FDA priority review voucher – Retail sees 'huge' buying opportunityOctober 7 at 2:19 PM | msn.comUltragenyx to sell FDA priority review voucher for $210MOctober 7 at 2:19 PM | seekingalpha.comUltragenyx shares rise after agreeing to sell FDA priority review voucher for $210 millionOctober 7 at 12:49 PM | proactiveinvestors.comUltragenyx Pharmaceutical (NASDAQ:RARE) CAO Theodore Alan Huizenga Sells 1,283 Shares of StockSeptember 16, 2026 | insidertrades.comSee More Headlines RARE Stock Analysis - Frequently Asked Questions How have RARE shares performed this year? Ultragenyx Pharmaceutical's stock was trading at $23.00 on January 1st, 2026. Since then, RARE shares have decreased by 33.5% and is now trading at $15.29. How were Ultragenyx Pharmaceutical's earnings last quarter? Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) posted its quarterly earnings results on Tuesday, August, 4th. The biopharmaceutical company reported ($0.90) earnings per share for the quarter, topping analysts' consensus estimates of ($1.22) by $0.32. The company's quarterly revenue was up 28.5% on a year-over-year basis. Read the conference call transcript. When did Ultragenyx Pharmaceutical IPO? Ultragenyx Pharmaceutical (RARE) raised $112 million in an IPO on Friday, January 31st 2014. The company issued 5,760,369 shares at $19.00-$20.00 per share. Who are Ultragenyx Pharmaceutical's major shareholders? Top institutional investors of Ultragenyx Pharmaceutical include Versant Capital Management Inc. Insiders that own company stock include Emil D Kakkis, Thomas Richard Kassberg, Eric Crombez, John Richard Pinion, Howard Horn, Karah Herdman Parschauer, Erik Harris, Theodore Alan Huizenga, Shehnaaz Suliman, Corazon (Corsee) D Sanders and Matthew K Fust. View institutional ownership trends. How do I buy shares of Ultragenyx Pharmaceutical? Shares of RARE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ultragenyx Pharmaceutical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ultragenyx Pharmaceutical investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Broadcom (AVGO), Adobe (ADBE), Advanced Micro Devices (AMD) and Arista Networks (ANET). Company Calendar Last Earnings8/04/2026Today10/08/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (1m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 RARE's financial health is in the Red zone, according to TradeSmith. RARE has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:RARE CIK1515673 Webwww.ultragenyx.com Phone(415) 483-8800Fax415-483-8810Employees1,371Year Founded2010Price Target and Rating Average Price Target for Ultragenyx Pharmaceutical$34.58 High Price Target$90.00 Low Price Target$16.00 Potential Upside/Downside+126.2%Consensus RatingHold Rating Score (0-4)2.48 Research Coverage21 Analysts Profitability EPS (Trailing Twelve Months)($5.84) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$575 million Net Margins-81.79% Pretax Margin-81.18% Return on EquityN/A Return on Assets-44.40% Debt Debt-to-Equity RatioN/A Current Ratio1.73 Quick Ratio1.56 Sales & Book Value Annual Sales$717 million Price / Sales2.10 Cash FlowN/A Price / Cash FlowN/A Book Value($0.83) per share Price / Book-18.42Miscellaneous Outstanding Shares98,589,000Free Float93,462,000Market Cap$1.51 billion OptionableOptionable Beta0.35 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:RARE) was last updated on 10/8/2026 by MarketBeat.com Staff. From Our PartnersChampion stock-picker warns, “Watch out for the Anthropic IPO”Matt McCall flagged AMD back in 2009, before it rose 25,000 percent, turning a 5,000 dollar stake into more th...Monument Traders Alliance | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredThe only 5 stocks that matterSpaceX's IPO reportedly minted 4,400 new millionaires, and OpenAI is said to be eyeing a 1 trillion dollar IPO...TradeSmith | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredElon's next millionaires start October 24?SpaceX minted 4,400 millionaires in a single day, and Tesla has turned more than 5,000 employees into milliona...Behind the Markets | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as Novemeber. It...Weiss Ratings | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ultragenyx Pharmaceutical Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ultragenyx Pharmaceutical With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
